Last reviewed · How we verify
dex
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that induces sedation and reduces sympathetic nervous system activity.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that induces sedation and reduces sympathetic nervous system activity. Used for Sedation in intensive care unit (ICU) patients, Sedation in procedural sedation.
At a glance
| Generic name | dex |
|---|---|
| Also known as | Ropivacaine/dex, dexmedetomidine group |
| Sponsor | The Cleveland Clinic |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine works by activating alpha-2 adrenergic receptors in the brain, which leads to a decrease in the activity of the sympathetic nervous system. This results in sedation, anxiolysis, and a decrease in blood pressure and heart rate. Additionally, dexmedetomidine has analgesic properties and can reduce the need for opioids in some patients.
Approved indications
- Sedation in intensive care unit (ICU) patients
- Sedation in procedural sedation
Common side effects
- Dry mouth
- Hypotension
- Bradycardia
- Nausea
- Headache
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |